Page 89 - Mployee Wellness Programs News Today

Avalon BioVentures unveiled new portfolio company Arialys Therapeutics. The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder.

This on-demand webinar explores the impact of poor data quality and methods to improve patient data quality. It highlights technology that can improve workflows to help reduce workforce burnout.

U.K. doctor David Watkins has been a public critic of Babylon Health and its AI technology for years, during which has received anonymous emails from Babylon employees who shared his concerns but feared to speak out publicly. After Babylon collapsed, a former employee publicly declared that the AI engine was indeed faulty. As a longtime skeptic of Babylon's claims surrounding its technology, Watkins said that Ali Parsa, the company's CEO, shouldn’t be treated any differently to Eliza...

Talkiatry, Array Behavioral Care, Iris Telehealth and Quartet Health sent a letter to the DEA asking for a special registration process that would allow for the prescribing of certain controlled medications via telemedicine.

Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.

Pumpspotting's funding round was led by Sincere Corporation and Maine Venture Fund and included participation from Unum Business Ventures and Maine Technology Institute. In total, pumpspotting has raised more than $3.3 million.

The FDA said the updated messenger RNA vaccines from Pfizer/BioNTech and Moderna will protect against the omicron subvariants now prevalent in circulation. Left out of the FDA decision is Novavax, whose protein-based vaccine is still under regulatory review.

The group of 10 startups in the accelerator have ambitions to improve early detection of lung cancer, eliminate contaminated needles, improve remote monitoring and provide new ways to treat head lice, among other goals.

Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.

In rural areas, the share of eligible beneficiaries enrolled in MA plans nearly quadrupled from 11% in 2010 to 40% in 2023, according to new research from KFF. This represents 400,000 rural MA beneficiaries in 2010 and 1.8 million in 2023.